ClinicalTrials.gg
CompletedNCT04774003ORION-14Updated Mar 25, 2025

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

A Phase 1 interventional study of 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) and Placebo in Hyperlipidemia, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing inclisiran in Hyperlipidemias — 5 open to participants now, 8 under way, 5 of them phase 3. inclisiran · Hyperlipidemias.

Enrollment
9th of 11
40 · median 300
Started
2021
with 3 others
Phase 1
Only one
of the 11
Registered
1st of 11
by date
Lead sponsor
9 of 11
Novartis Pharmaceuticals

Among the 11 studies testing inclisiran in Hyperlipidemias, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 1, and was the 1st registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

5 of the 11 studies testing inclisiran in Hyperlipidemias are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing inclisiran in Hyperlipidemias, or all of them as a file.
02

Study summary

Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with LDL-C lowering therapies

Read the detailed description

The purpose of the study is to characterize pharmacokinetics, pharmacodynamics, safety and tolerability of inclisiran in Chinese participants with elevated serum LDL-C to support inclisiran registration in China.Inclisiran is a long acting RNA therapeutic agent that inhibits the synthesis of PCSK9, leading to reduced circulating LDL-C levels. Three pivotal Phase III studies have been conducted primarily in non-Asian participants to support New Drug Application/Marketing Authorization Application approval of inclisiran globally. This study design is based on the hypothesis that the global inclisiran clinical data primarily obtained in Caucasian participants could be appropriately extrapolated to Chinese participants.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • Inclisiran
  • KJX839
  • LDL-C
  • Pharmacokinetics and pharmacodynamics
  • Chinese participants with elevated serum LDL-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed.
  2. Male or female participants ≥ 18 years of age at screening
  3. Participants should meet fasting serum LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L) at screening
  4. Participants should meet fasting triglyceride \< 400 mg/dL (\< 4.52 mmol/L) at screening
  5. Participants should be receiving a maximally tolerated dose of statin#.
  6. For all participants, all the lipid-lowering therapy/ies (such as but not limited to statins and/or ezetimibe) should have remained stable (stable dose and no medication change) for ≥ 30 days before screening with no planned medication or dose change during study participation. #Maximum tolerated dose was defined as the maximum dose of statin that could be taken on a regular basis without intolerable AEs.
  7. Participants not receiving statin must have a documented evidence of intolerance to all doses of at least 2 different statins (or the corresponding local definition of complete intolerance to statins)

Exclusion criteria

Exclusion Criteria:

  1. Participants diagnosed with any of following: homozygous familial hypercholesterolemia, class III \& IV heart failure, Type 2 diabetes, severe hypertension, active liver disease, infection or any uncontrolled or serious disease;
  2. History of drug abuse or unhealthy alcohol use, of any organ system, or or allergy to the compound/compound class;
  3. Major adverse cardiovascular event within 3 months prior to randomization;
  4. Calculated ≤30 mL/min by estimated glomerular filtration rate (eGFR) using standardized clinical methodology;
  5. Use of other investigational drugs or planned use of other investigational products or devices;
  6. Women of unless they are using basic methods of during dosing of investigational drug (total abstinence, sterilization, barrier methods, hormonal contraception, intrauterine device);
  7. Treatment with monoclonal antibodies inhibiting PCSK9 within 90 days prior to screening.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    300 mg inclisiran sodium (equivalent to 284 mg inclisiran)

    300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1

    Drug: 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)

  • Experimental
    100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)

    100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1

    Drug: 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)

  • Placebo comparator
    Placebo

    Placebo x 1 dose (n=10) at Day 1

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameters (Cmax) maximum peak observed plasma inclisiran concentration in treated participants

    Pharmacokinetics parameters of inclisiran

    Time frame: 0-48 hours post-dose

  2. PK parameters (Tmax) time to reach maximum peak plasma inclisiran concentration in treated participants

    Pharmacokinetics parameters of inclisiran

    Time frame: 0-48 hours post-dose

  3. PK parameters (T1/2) the elimination half-life associated with the terminal slope of a semi-logarithmic concentration-time curve in inclisiran treated participants

    Pharmacokinetics parameters of inclisiran

    Time frame: 0-48 hours post-dose

  4. PK parameters (AUC) area under the plasma concentration-time curve in inclisiran treated participants

    Pharmacokinetics parameters of inclisiran

    Time frame: 0-48 hours post-dose

  5. Percentage change in Proprotein convertase subtilisin kexin 9 (PCSK9) from baseline overtime

    Pharmacodynamics effects of inclisiran

    Time frame: Baseline to Days 5, 8, 15, 30, 60 and 90

  6. Percentage change in Low density lipoprotein cholesterol (LDL-C) from baseline overtime

    Pharmacodynamics effects of inclisiran

    Time frame: Baseline to Days 5, 8, 15, 30, 60 and 90

Secondary outcomes

  1. Percent change from baseline to Days 30, 60 and 90 in PD parameter Proprotein convertase subtilisin kexin 9 (PCSK9)

    Pharmacodynamics differences between inclisiran and placebo

    Time frame: Baseline to Days 30, 60 and 90

  2. Percent change from baseline to Days 30, 60 and 90 in PD parameter Low density lipoprotein cholesterol (LDL-C)

    Pharmacodynamics differences between inclisiran and placebo

    Time frame: Baseline to Days 30, 60 and 90

  3. Rate of formation of anti-drug antibodies to Inclisiran

    Immunogenicity of inclisiran

    Time frame: Baseline, Days 30 and 90

07

Study locations

3 sites
  • Novartis Investigative Site
    Changsha, Hunan 410003, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100029, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2021, 7 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 7 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 26, 2021
StartActual
Feb 26, 2021
Primary completionActual
Oct 18, 2021
CompletionActual
Oct 18, 2021
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04774003
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Feb 26, 2021
Primary completion
Oct 18, 2021
Completion
Oct 18, 2021
Last update
Mar 25, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion